GB9606452D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB9606452D0
GB9606452D0 GBGB9606452.2A GB9606452A GB9606452D0 GB 9606452 D0 GB9606452 D0 GB 9606452D0 GB 9606452 A GB9606452 A GB 9606452A GB 9606452 D0 GB9606452 D0 GB 9606452D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
deoxyspergualine
ctla4
azathioprine
cyclosporin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9606452.2A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
Original Assignee
Sandoz AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10791127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB9606452(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sandoz AG filed Critical Sandoz AG
Priority to GBGB9606452.2A priority Critical patent/GB9606452D0/en
Publication of GB9606452D0 publication Critical patent/GB9606452D0/en
Priority to IDP970980A priority patent/ID17195A/id
Priority to MYPI97001258A priority patent/MY117798A/en
Priority to ES08017336T priority patent/ES2421455T3/es
Priority to IL12581297A priority patent/IL125812A/en
Priority to KR1020077008212A priority patent/KR20070083654A/ko
Priority to TR1998/01919T priority patent/TR199801919T2/xx
Priority to PCT/EP1997/001548 priority patent/WO1997035575A1/en
Priority to PT97915441T priority patent/PT893996E/pt
Priority to CZ19983070A priority patent/CZ292483B6/cs
Priority to HK99103744.5A priority patent/HK1018688B/xx
Priority to EP97915441A priority patent/EP0893996B1/en
Priority to HU0001267A priority patent/HU226422B1/hu
Priority to PL97328659A priority patent/PL187732B1/pl
Priority to DE69715611T priority patent/DE69715611T2/de
Priority to EP08017336.2A priority patent/EP2008657B1/en
Priority to SI9730405T priority patent/SI0893996T1/xx
Priority to DK08017336.2T priority patent/DK2008657T3/da
Priority to AU22918/97A priority patent/AU716514B2/en
Priority to PT80173362T priority patent/PT2008657E/pt
Priority to DK97915441T priority patent/DK0893996T3/da
Priority to KR1020057005463A priority patent/KR100836971B1/ko
Priority to RU98119312/14A priority patent/RU2214247C2/ru
Priority to JP9532077A priority patent/JP2000507226A/ja
Priority to SK1327-98A priority patent/SK284343B6/sk
Priority to NZ331463A priority patent/NZ331463A/en
Priority to AT97915441T priority patent/ATE224194T1/de
Priority to CA2247275A priority patent/CA2247275C/en
Priority to BR9708358A priority patent/BR9708358A/pt
Priority to CN97193278A priority patent/CN1124135C/zh
Priority to EP01116262A priority patent/EP1149581A3/en
Priority to SI9730801T priority patent/SI2008657T1/sl
Priority to ES97915441T priority patent/ES2184078T3/es
Priority to ZA972719A priority patent/ZA972719B/xx
Priority to NO19984340A priority patent/NO316667B1/no
Priority to US09/712,359 priority patent/US6384046B1/en
Priority to US10/092,639 priority patent/US20020127248A1/en
Priority to CY0400004A priority patent/CY2404B1/xx
Priority to JP2008314494A priority patent/JP5124431B2/ja
Priority to US12/715,007 priority patent/US20100152105A1/en
Priority to US13/357,199 priority patent/US20120177690A1/en
Priority to US14/197,368 priority patent/US20140187574A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9606452.2A 1996-03-27 1996-03-27 Organic compounds Pending GB9606452D0 (en)

Priority Applications (42)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds
IDP970980A ID17195A (id) 1996-03-27 1997-03-25 Pemakaian turunan-turunan rapamisin pada vaskulofati dan senotransplantasi
MYPI97001258A MY117798A (en) 1996-03-27 1997-03-25 Use of a rapamycin derivative in vasculopathies and xenotransplantation
SI9730801T SI2008657T1 (sl) 1996-03-27 1997-03-26 Uporaba rapamicinskih derivatov pri vaskulopatijah
ES97915441T ES2184078T3 (es) 1996-03-27 1997-03-26 Uso de derivados de rapamicina en vasculopatias y xenotrasplantes.
PT80173362T PT2008657E (pt) 1996-03-27 1997-03-26 Uso de derivados da rapamicina em vasculopatias
RU98119312/14A RU2214247C2 (ru) 1996-03-27 1997-03-26 Применение производных рапамицина при вазопатиях и ксенотрансплантации
KR1020077008212A KR20070083654A (ko) 1996-03-27 1997-03-26 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도
TR1998/01919T TR199801919T2 (xx) 1996-03-27 1997-03-26 Rapamisin t�revlerinin damar hastal�klar� ve yabanc� doku naklinde kullan�m�.
PCT/EP1997/001548 WO1997035575A1 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation
PT97915441T PT893996E (pt) 1996-03-27 1997-03-26 Uso de derivados de rapamicina em vasculopatias e em xenotransplantacao
CZ19983070A CZ292483B6 (cs) 1996-03-27 1997-03-26 Farmaceutická kompozice obsahující 40-O-(2-hydroxy)ethylrapamycin
HK99103744.5A HK1018688B (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopqthies and xenotransplantation
EP97915441A EP0893996B1 (en) 1996-03-27 1997-03-26 Use of a rapamycin derivative in vasculopathies and xenotransplantation
HU0001267A HU226422B1 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives for the preparation of pharmaceutical compositions treating vasculopathies
PL97328659A PL187732B1 (pl) 1996-03-27 1997-03-26 Zastosowanie pochodnej rapamycyny w waskulopatii i przeszczepach międzygatunkowych
DE69715611T DE69715611T2 (de) 1996-03-27 1997-03-26 Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen
EP08017336.2A EP2008657B1 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies
SI9730405T SI0893996T1 (en) 1996-03-27 1997-03-26 Use of a rapamycin derivative in vasculopathies and xenotransplantation
DK08017336.2T DK2008657T3 (da) 1996-03-27 1997-03-26 Anvendelse af rapamycinderivater ved karforandringer
AU22918/97A AU716514B2 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation
ES08017336T ES2421455T3 (es) 1996-03-27 1997-03-26 Uso de derivados de rapamicina en vasculopatías
DK97915441T DK0893996T3 (da) 1996-03-27 1997-03-26 Anvendelse af et rapamycinderivat til behandling af karsygdomme og xenotransplantationer
KR1020057005463A KR100836971B1 (ko) 1996-03-27 1997-03-26 맥관 장애 및 이종 이식술에서의 라파마이신 유도체의 용도
IL12581297A IL125812A (en) 1996-03-27 1997-03-26 Pharmaceutical compositions comprising 40-o-(2-hydroxyethyl)-rapamycin for use in vasculopathies and xenotransplantation and the novel combination of the compound with mycophenolic acid, mycophenolate mofetil or ctla4-ig
JP9532077A JP2000507226A (ja) 1996-03-27 1997-03-26 血管疾病および異種移植におけるラパマイシン誘導体の使用
SK1327-98A SK284343B6 (sk) 1996-03-27 1997-03-26 Použitie 40-O-(2-hydroxy)etyl-rapamycínu
NZ331463A NZ331463A (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation
AT97915441T ATE224194T1 (de) 1996-03-27 1997-03-26 Verwendung eines rapamycinderivates zur behandlung von gefäss erkrankungen und xenotransplantationen
CA2247275A CA2247275C (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation
BR9708358A BR9708358A (pt) 1996-03-27 1997-03-26 Uso de derivados de rapamicina em vasculopatias e xenotransplantes
CN97193278A CN1124135C (zh) 1996-03-27 1997-03-26 雷帕霉素衍生物在血管病和异种移植中的应用
EP01116262A EP1149581A3 (en) 1996-03-27 1997-03-26 Use of rapamycin derivatives in vasculopathies and xenotransplantation
ZA972719A ZA972719B (en) 1996-03-27 1997-03-27 Use of rapamycin derivatives in vasculopathies and xenotransplantations
NO19984340A NO316667B1 (no) 1996-03-27 1998-09-18 Anvendelsen av 40-O-(2-hydroksy)etyl-rapamycin ved fremstilling av medikamenter
US09/712,359 US6384046B1 (en) 1996-03-27 2000-11-14 Use of 40-O-(2-hydroxy)ethylrapamycin for treatment of restenosis and other disorders
US10/092,639 US20020127248A1 (en) 1996-03-27 2002-03-07 Use of rapamycin derivatives in vasculop atheis and xenotransplantation
CY0400004A CY2404B1 (en) 1996-03-27 2004-01-08 Use of rapamycin derivatives in vasculopathies andxenotransplantation.
JP2008314494A JP5124431B2 (ja) 1996-03-27 2008-12-10 血管疾病および異種移植におけるラパマイシン誘導体の使用
US12/715,007 US20100152105A1 (en) 1996-03-27 2010-03-01 Use of rapamycin derivatives in chronic rejection
US13/357,199 US20120177690A1 (en) 1996-03-27 2012-01-24 Use of rapamycin derivatives in vasculopathies and xenotransplantation
US14/197,368 US20140187574A1 (en) 1996-03-27 2014-03-05 Use of rapamycin derivatives in vasculopathies and xenotransplantation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9606452.2A GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds

Publications (1)

Publication Number Publication Date
GB9606452D0 true GB9606452D0 (en) 1996-06-05

Family

ID=10791127

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9606452.2A Pending GB9606452D0 (en) 1996-03-27 1996-03-27 Organic compounds

Country Status (29)

Country Link
US (5) US6384046B1 (cg-RX-API-DMAC10.html)
EP (3) EP0893996B1 (cg-RX-API-DMAC10.html)
JP (2) JP2000507226A (cg-RX-API-DMAC10.html)
KR (2) KR100836971B1 (cg-RX-API-DMAC10.html)
CN (1) CN1124135C (cg-RX-API-DMAC10.html)
AT (1) ATE224194T1 (cg-RX-API-DMAC10.html)
AU (1) AU716514B2 (cg-RX-API-DMAC10.html)
BR (1) BR9708358A (cg-RX-API-DMAC10.html)
CA (1) CA2247275C (cg-RX-API-DMAC10.html)
CY (1) CY2404B1 (cg-RX-API-DMAC10.html)
CZ (1) CZ292483B6 (cg-RX-API-DMAC10.html)
DE (1) DE69715611T2 (cg-RX-API-DMAC10.html)
DK (2) DK0893996T3 (cg-RX-API-DMAC10.html)
ES (2) ES2184078T3 (cg-RX-API-DMAC10.html)
GB (1) GB9606452D0 (cg-RX-API-DMAC10.html)
HU (1) HU226422B1 (cg-RX-API-DMAC10.html)
ID (1) ID17195A (cg-RX-API-DMAC10.html)
IL (1) IL125812A (cg-RX-API-DMAC10.html)
MY (1) MY117798A (cg-RX-API-DMAC10.html)
NO (1) NO316667B1 (cg-RX-API-DMAC10.html)
NZ (1) NZ331463A (cg-RX-API-DMAC10.html)
PL (1) PL187732B1 (cg-RX-API-DMAC10.html)
PT (2) PT2008657E (cg-RX-API-DMAC10.html)
RU (1) RU2214247C2 (cg-RX-API-DMAC10.html)
SI (1) SI2008657T1 (cg-RX-API-DMAC10.html)
SK (1) SK284343B6 (cg-RX-API-DMAC10.html)
TR (1) TR199801919T2 (cg-RX-API-DMAC10.html)
WO (1) WO1997035575A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA972719B (cg-RX-API-DMAC10.html)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
DE69736750T2 (de) 1996-07-30 2007-08-16 Novartis Ag Pharmazeutische zusammensetzungen zur behandlung der transplantatabstossung sowie der autoimmun- oder entzündlichen zustände
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US20030129215A1 (en) * 1998-09-24 2003-07-10 T-Ram, Inc. Medical devices containing rapamycin analogs
WO2000067773A2 (en) * 1999-05-10 2000-11-16 Novartis Ag Combinations of immunosupressive agents for the treatment or prevention of graft rejections
US7807211B2 (en) 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US6790228B2 (en) 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070055367A1 (en) * 2000-03-15 2007-03-08 Orbus Medical Technologies, Inc. Medical device with coating that promotes endothelial cell adherence and differentiation
US8460367B2 (en) * 2000-03-15 2013-06-11 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
WO2001068158A1 (en) 2000-03-15 2001-09-20 Orbus Medical Technologies Inc. Coating that promotes endothelial cell adherence
US20030229393A1 (en) * 2001-03-15 2003-12-11 Kutryk Michael J. B. Medical device with coating that promotes cell adherence and differentiation
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US20070141107A1 (en) * 2000-03-15 2007-06-21 Orbusneich Medical, Inc. Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
US20050002986A1 (en) * 2000-05-12 2005-01-06 Robert Falotico Drug/drug delivery systems for the prevention and treatment of vascular disease
US7300662B2 (en) 2000-05-12 2007-11-27 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US8236048B2 (en) 2000-05-12 2012-08-07 Cordis Corporation Drug/drug delivery systems for the prevention and treatment of vascular disease
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1709974A3 (en) * 2000-06-16 2006-12-06 Wyeth Method of treating cardiovascular disease using rapamycin
WO2002026139A1 (en) 2000-09-29 2002-04-04 Cordis Corporation Coated medical devices
CN1551767A (zh) * 2001-02-19 2004-12-01 ��˹��ŵ�� 癌症的治疗
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US7682387B2 (en) 2002-04-24 2010-03-23 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
WO2003070275A1 (en) * 2002-02-22 2003-08-28 Prophy Med Ab Use of an inhibitor or antagonist against tissue factor
US20040024450A1 (en) * 2002-04-24 2004-02-05 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
CN1655738A (zh) * 2002-05-20 2005-08-17 奥勃斯医学技术股份有限公司 可植入的药物洗脱医疗装置
US8109987B2 (en) 2003-04-14 2012-02-07 Tryton Medical, Inc. Method of treating a lumenal bifurcation
US7279174B2 (en) 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
US7220755B2 (en) 2003-11-12 2007-05-22 Biosensors International Group, Ltd. 42-O-alkoxyalkyl rapamycin derivatives and compositions comprising same
US9114198B2 (en) 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
WO2005107817A2 (en) * 2004-04-30 2005-11-17 Orbus Medical Technologies, Inc. Medical device with coating for capturing genetically-altered cells and methods of using same
EP1768662A2 (en) 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Small molecule immunopotentiators and assays for their detection
US8709469B2 (en) 2004-06-30 2014-04-29 Abbott Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7901451B2 (en) 2004-09-24 2011-03-08 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method for treating restenosis
US20060194829A1 (en) * 2004-12-20 2006-08-31 Clackson Timothy P Therapeutic materials and methods
AU2006315512B2 (en) 2005-11-14 2012-11-01 Ariad Pharmaceuticals, Inc. Administration of an mTOR inhibitor to treat patients with cancer
CN101340859B (zh) * 2005-11-17 2010-12-15 路嘉株式会社 用于制备在对身体的医疗手术中使用的插入物的方法
US20070173923A1 (en) * 2006-01-20 2007-07-26 Savage Douglas R Drug reservoir stent
US7867988B2 (en) 2006-09-13 2011-01-11 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
US20080097591A1 (en) 2006-10-20 2008-04-24 Biosensors International Group Drug-delivery endovascular stent and method of use
US8067055B2 (en) * 2006-10-20 2011-11-29 Biosensors International Group, Ltd. Drug-delivery endovascular stent and method of use
US20080103584A1 (en) * 2006-10-25 2008-05-01 Biosensors International Group Temporal Intraluminal Stent, Methods of Making and Using
KR100930167B1 (ko) * 2007-09-19 2009-12-07 삼성전기주식회사 초광각 광학계
US8661630B2 (en) 2008-05-21 2014-03-04 Abbott Cardiovascular Systems Inc. Coating comprising an amorphous primer layer and a semi-crystalline reservoir layer
CA2705764C (en) 2007-11-14 2016-08-02 Biosensors International Group, Ltd. Automated stent coating apparatus and method
EP2245165A4 (en) * 2008-01-11 2011-06-01 Massachusetts Eye & Ear Infirm TRANSGENIC CONDITIONAL STOP DIMERICABLE CASPASE ANIMALS
EP2352459A4 (en) * 2008-10-03 2013-09-25 Elixir Medical Corp MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE
US8366763B2 (en) 2009-07-02 2013-02-05 Tryton Medical, Inc. Ostium support for treating vascular bifurcations
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
UA104738C2 (ru) 2011-05-18 2014-03-11 Олег Миколайович Лазаренко Композиция для повышения биосовместимости имплантатов и клеток для трансплантации с организмом реципиента и способ ее приготовления
CN102268015B (zh) * 2011-08-30 2013-08-28 成都摩尔生物医药有限公司 一种依维莫司的合成方法
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
KR101723265B1 (ko) 2013-08-16 2017-04-04 가톨릭대학교 산학협력단 mTOR/STAT3 신호억제제 처리된 면역조절능을 갖는 간엽줄기세포 및 이를 포함하는 면역질환의 예방 또는 치료용 세포치료제 조성물
CA3059017C (en) 2013-09-24 2021-05-25 Giner Life Sciences, Inc. System for gas treatment of a cell implant
CN106061482A (zh) 2013-10-08 2016-10-26 拉姆医疗公司 用于治疗淋巴管平滑肌瘤病的雷帕霉素
RU2016136348A (ru) 2014-02-11 2018-03-16 Лэм Терапьютикс, Инк. Рапамицин для лечения лимфангиолейомиоматоза
US10307371B2 (en) 2014-02-11 2019-06-04 AI Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
NZ724756A (en) 2014-04-04 2023-07-28 Ai Therapeutics Inc An inhalable rapamycin formulation for treating age-related conditions
CA2963085C (en) 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
WO2016130645A1 (en) 2015-02-10 2016-08-18 Lam Therapeutics, Inc. Rapamycin for the treatment of lymphangioleiomyomatosis
US20190167649A1 (en) 2016-08-10 2019-06-06 The Board Of Regents Of The University Of Texas System Topical rapamycin therapy
CN109715224B (zh) 2016-09-19 2022-02-22 百多力股份公司 无聚合物的药物洗脱血管支架
JP6993003B2 (ja) 2016-11-15 2022-01-13 ガイナー ライフ サイエンシズ,インク. 皮下インプラントとの使用に適した経皮的ガス拡散装置
US11826492B2 (en) 2016-12-22 2023-11-28 Biotronik Ag Intratumoral drug delivery materials and methods for treating breast cancer
EP3618916A4 (en) 2017-05-04 2021-04-14 Giner Life Sciences, Inc. ROBUST IMPLANTABLE GAS DISPENSING DEVICE AND PROCEDURES, SYSTEMS AND DEVICES THEREFORE
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
LT3898637T (lt) 2018-12-18 2025-03-10 Novartis Ag Rapamicino dariniai
AU2020226527A1 (en) 2019-02-20 2021-10-14 AI Therapeutics, Inc. Topical rapamycin formulations and their use in treating facial angiofibromas and other skin disorders
KR20260115158A (ko) 2019-03-26 2026-07-23 노파르티스 아게 이소티아졸리딘 1,1-디옥시드 및 1,4-부탄 술톤 함유 라파마이신 유도체 및 이의 용도

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639724A (en) * 1984-07-24 1997-06-17 Sandoz Ltd. Cyclosporin galenic forms
US5364612A (en) * 1991-05-06 1994-11-15 Immunomedics, Inc. Detection of cardiovascular lesions
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
US5516781A (en) * 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
CA2086642C (en) * 1992-01-09 2004-06-15 Randall E. Morris Method of treating hyperproliferative vascular disease
CA2094858C (en) * 1992-04-28 2004-06-15 Robert D. Mitchell Method of treating hyperproliferative vascular disease
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5283257A (en) * 1992-07-10 1994-02-01 The Board Of Trustees Of The Leland Stanford Junior University Method of treating hyperproliferative vascular disease
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
BR9408323A (pt) * 1993-12-17 1997-08-19 Sandoz Ag Derivados de rapamicina
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6265427B1 (en) * 1995-06-07 2001-07-24 The Proctor & Gamble Company Pharmaceutical composition for the method of treating leukemia
DE69624921T2 (de) * 1995-06-09 2003-09-11 Novartis Ag, Basel Rapamycinderivate
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds

Also Published As

Publication number Publication date
DK0893996T3 (da) 2002-12-09
SK284343B6 (sk) 2005-02-04
DK2008657T3 (da) 2013-07-22
NZ331463A (en) 2001-10-26
EP2008657B1 (en) 2013-04-24
EP0893996B1 (en) 2002-09-18
KR20050038656A (ko) 2005-04-27
MY117798A (en) 2004-08-30
PT2008657E (pt) 2013-07-12
CY2404B1 (en) 2004-09-10
IL125812A0 (en) 1999-04-11
HUP0001267A2 (hu) 2000-11-28
WO1997035575A1 (en) 1997-10-02
ID17195A (id) 1997-12-11
HK1018688A1 (en) 1999-12-30
CN1124135C (zh) 2003-10-15
PL187732B1 (pl) 2004-09-30
SI2008657T1 (sl) 2013-07-31
AU716514B2 (en) 2000-02-24
NO316667B1 (no) 2004-03-29
NO984340L (no) 1998-09-18
JP2000507226A (ja) 2000-06-13
CZ307098A3 (cs) 1999-01-13
US20140187574A1 (en) 2014-07-03
BR9708358A (pt) 1999-08-03
ZA972719B (en) 1998-09-28
EP2008657A3 (en) 2009-02-04
US20120177690A1 (en) 2012-07-12
CA2247275A1 (en) 1997-10-02
US20020127248A1 (en) 2002-09-12
JP5124431B2 (ja) 2013-01-23
ES2421455T3 (es) 2013-09-02
EP1149581A3 (en) 2003-12-03
SK132798A3 (en) 1999-03-12
US6384046B1 (en) 2002-05-07
JP2009102349A (ja) 2009-05-14
EP2008657A2 (en) 2008-12-31
ES2184078T3 (es) 2003-04-01
EP0893996A1 (en) 1999-02-03
US20100152105A1 (en) 2010-06-17
PL328659A1 (en) 1999-02-15
ATE224194T1 (de) 2002-10-15
KR100836971B1 (ko) 2008-06-10
HU226422B1 (en) 2008-12-29
KR20070083654A (ko) 2007-08-24
NO984340D0 (no) 1998-09-18
EP1149581A2 (en) 2001-10-31
DE69715611D1 (de) 2002-10-24
PT893996E (pt) 2002-12-31
HUP0001267A3 (en) 2002-01-28
AU2291897A (en) 1997-10-17
CN1214631A (zh) 1999-04-21
DE69715611T2 (de) 2003-05-22
TR199801919T2 (xx) 1999-02-22
CZ292483B6 (cs) 2003-09-17
CA2247275C (en) 2011-10-11
RU2214247C2 (ru) 2003-10-20
IL125812A (en) 2001-12-23

Similar Documents

Publication Publication Date Title
ZA972719B (en) Use of rapamycin derivatives in vasculopathies and xenotransplantations
EA200000848A1 (ru) Способ селективного снижения числа или активности макрофагов (варианты), способ лечения или профилактики заболевания субъекта (варианты), способ диагностики заболевания у субъекта
IL140137A0 (en) Receptor bodies specifically binding tie-2 ligands
PY0101639A (es) Method of treating restenosis with rapamycin
FI963101A7 (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoo n, joissa seerumin interleukiini-6-taso on kohonnut
ES2185751T3 (es) Prepolimeros terminados en isocianato de viscosidad estable y polioxialquileno polieter polioles con estabilidad de almacenamiento mejorada.
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
IL127623A0 (en) Tie-2 receptor ligands (tie ligand-3; tie ligand-4) and their uses
DE69816796D1 (de) Pharmazeutische oder nahrungsmittelzusammensetzung für die behandlung von pathologien die assoziiert sind mit einem transplantatabstoss, einer allergischen oder autoimmunreaktion
DE69522564D1 (de) Alkalibeständiges proteinadsorbens
DE69225791D1 (de) Monoklonale Antikörper gegen Tetanustoxin und sie enthaltende pharmazeutische Zusammensetzungen
ZA951293B (en) 4-amino derivatives of 5-substituted mycophenolic acid
AU653332B2 (en) Synthetic peptides which contain sequences from factor VIIa, and the use thereof
DE50210279D1 (de) Screeningverfahren mit bnpi und dnpi
Nguyet An Investigation into Strategies to Develop Pronunciation Skills for First-year Non-English-majored Students at Thuongmai University
EP0791360A3 (en) Treatment of septic shock with anti-TNF antibodies
ATE134988T1 (de) Neue vorangeordnete sechszähnige liganden verwendbar in röntgenologischen bildformenden wirkstoffen
Pioli Reactivation failure in infants: A processing analysis.
RU96118013A (ru) Способ реконструкции молочной железы
Smith et al. Elimination of leprosy and prospects for rehabilitation.
ATE362377T1 (de) Therapeutische konjugate die die vaskuläre glatten muskelzellen inhibitieren
Bertschy et al. Vulnerability to fluoxetine-induced indifference syndrome among opiate addicts: a case report.
ES1033555U (es) Juego de pelota en espiral.
ATE336503T1 (de) Cyclophilin als allergen identifiziert

Legal Events

Date Code Title Description
730 Substitution of applicants allowed (sect. 30/1977)